M&A - Scilex Holding Co
Form Type: 8-K
Filing Date: 2025-04-21
Corporate Action: Merger
Type: Update
Accession Number: 000095017025056022
Filing Summary: On April 16, 2025, Scilex Holding Company’s subsidiary, Semnur Pharmaceuticals, Inc., entered into Amendment No. 1 to the Merger Agreement with Denali Capital Acquisition Corp. The Amendment modifies certain covenants of the parties due to the de-listing of Parent Securities from the Nasdaq. It extends the time for Denali to complete the business combination with Semnur to December 11, 2025. Additionally, it modifies the Outside Date to September 30, 2025. The Merger Agreement pertains to the merger of Semnur into Denali Merger Sub Inc., resulting in Semnur becoming a wholly owned subsidiary of Denali. The Business Combination is subject to various regulatory approvals, and a definitive proxy statement will be sent to Denali shareholders regarding the transaction. Investors are advised to review the materials for important information about the Business Combination.
Additional details:
Item Name: merger_agreement_date
Item Value: 2024-08-30
Item Name: amendment_date
Item Value: 2025-04-16
Item Name: parent_company
Item Value: Denali Capital Acquisition Corp.
Item Name: surviving_company
Item Value: Semnur Pharmaceuticals, Inc.
Item Name: new_outside_date
Item Value: 2025-09-30
Item Name: extension_date
Item Value: Mutual agreement
Item Name: business_combination_description
Item Value: Merger of Semnur with Denali Merger Sub Inc.
Comments
No comments yet. Be the first to comment!